The KMT2C antibody is a research tool designed to detect KMT2C (lysine methyltransferase 2C), a protein encoded by the *KMT2C* gene in humans. Also known as MLL3. KMT2C belongs to the COMPASS family of histone methyltransferases, which catalyze the methylation of histone H3 at lysine 4 (H3K4), a modification associated with active gene transcription. KMT2C plays a critical role in regulating chromatin structure and gene expression, particularly in development, cellular differentiation, and tumor suppression.
Mutations or dysregulation of KMT2C are linked to cancers (e.g., breast, lung, bladder) and neurodevelopmental disorders. Researchers use KMT2C antibodies in techniques like Western blotting, immunohistochemistry, and ChIP-seq to study its expression, localization, and interaction with chromatin. These antibodies help investigate KMT2C’s role in epigenetic regulation, its involvement in disease mechanisms, and its potential as a therapeutic target.
Validation of KMT2C antibodies is crucial, as cross-reactivity with related family members (e.g., KMT2A/B/D) can occur. High-quality antibodies are often verified using knockout cell lines or siRNA knockdown to ensure specificity. Current studies focus on KMT2C’s partnership with tumor suppressors (e.g., p53) and its impact on enhancer regions, shedding light on its dual roles in maintaining genomic stability and modulating transcriptional programs.